Patient-Reported Outcome Response and Safety Profile in Patients With Moderately to Severely Active Rheumatoid Arthritis Treated With Baricitinib 2-mg

被引：1
|
作者：
Sholter, Dalton [1 ]
Wu, Jianmin [2 ]
Jia, Bochao [2 ]
Zhang, Hong [3 ]
Griffing, Kirstin [2 ]
Quebe, Amanda [2 ]
Birt, Julie [2 ]
Reis, Paulo [2 ]
Liu, Huaxiang [4 ]
Bingham, Clifton [5 ]
机构：
[1] Univ Alberta, Edmonton, AB, Canada
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] TechData Serv, Prussia, PA USA
[4] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[5] Johns Hopkins Arthrit Ctr, Baltimore, MD USA
来源：
JOURNAL OF RHEUMATOLOGY | 2021年 / 48卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
7
引用
收藏
页码：1109 / 1110
页数：2
相关论文
共 50 条
  • [21] PATIENT DISEASE TRAJECTORIES IN BARICITINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE
    Taylor, Peter C.
    Emery, Paul
    Weinblatt, Michael E.
    Mysler, Eduardo
    Rubbert-Roth, Andrea
    Jia, Bochao
    Sun, Luna
    Liu, Yushi
    Chen, Yun-Fei
    Cardoso, Anabela
    Tanaka, Yoshiya
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 322 - 323
  • [22] Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate
    Buch, Maya H.
    Walker, David
    Edwards, Christopher J.
    Barry, Jane
    Akroyd, Laura
    Omoruyi, Edmund V. Ekoka
    Taylor, Peter C.
    RHEUMATOLOGY, 2024,
  • [23] Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study
    Yang, Yue
    Xu, Jianhua
    Xu, Jian
    Li, Xingfu
    Hu, Jiankang
    Li, Xiangpei
    Zhang, Xiao
    He, Dongyi
    Bao, Chunde
    Li, Zhijun
    Wang, Guochun
    Zerbini, Cristiano A. F.
    Spindler, Alberto J.
    Kannowski, Carol L.
    Wu, Hanjun
    Ji, Fei
    Zhan, Lujing
    Liu, Mengru
    Li, Zhanguo
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13
  • [24] Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate
    Vera-Llonch, M.
    Massarotti, E.
    Wolfe, F.
    Shadick, N.
    Westhovens, R.
    Sofrygin, O.
    Maclean, R.
    Yuan, Y.
    Oster, G.
    RHEUMATOLOGY, 2008, 47 (04) : 535 - 541
  • [25] Efficacy of Long-term Treatment With Baricitinib 2 mg in Patients With Active Rheumatoid Arthritis
    Wells, Alvin
    Jia, Bochao
    Xie, Li
    Valenzuela, Guillermo
    Keystone, Edward
    Li, Zhanguo
    Quebe, Amanda
    Griffing, Kirstin
    Otawa, Susan
    Haraoui, Boulos
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1175 - 1175
  • [26] Efficacy of Long-term Treatment with Baricitinib 2 Mg in Patients with Active Rheumatoid Arthritis
    Wells, Alvin
    Jia, Bochao
    Xie, Li
    Valenzuela, Guillermo
    Keystone, Edward C.
    Li, Zhanguo
    Quebe, Amanda
    Griffing, Kirstin
    Otawa, Susan
    Haraoui, Boulos
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [27] Integrated Safety of Filgotinib in Patients with Moderately or Severely Active Rheumatoid Arthritis Receiving Treatment for up to 5.5 Years
    Winthrop, Kevin
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    Kivitz, Alan
    Matzkies, Franziska
    Genovese, Mark
    Jiang, Deyuan
    Chen, Kun
    Bartok, Beatrix
    Jahreis, Angelika
    Besuyen, Robin
    Burmester, Gerd
    Gottenberg, Jacques-Eric
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [28] Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials
    Sholter, Dalton
    Wu, Jianmin
    Jia, Bochao
    Zhang, Hong
    Griffing, Kirstin
    Birt, Julie
    Reis, Paulo Jorge Simoes
    Liu, Huaxiang
    Bingham, Clifton O., III
    RHEUMATOLOGY AND THERAPY, 2022, 9 (02) : 541 - 553
  • [29] Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials
    Dalton Sholter
    Jianmin Wu
    Bochao Jia
    Hong Zhang
    Kirstin Griffing
    Julie Birt
    Paulo Jorge Simoes Reis
    Huaxiang Liu
    Clifton O. Bingham
    Rheumatology and Therapy, 2022, 9 : 541 - 553
  • [30] Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
    Michael Schiff
    Tsutomu Takeuchi
    Roy Fleischmann
    Carol L. Gaich
    Amy M. DeLozier
    Douglas Schlichting
    Wen-Ling Kuo
    Ji-Eon Won
    Tara Carmack
    Terence Rooney
    Patrick Durez
    Saeed Shaikh
    Rodolfo Pardo Hidalgo
    Ronald van Vollenhoven
    Cristiano A. F. Zerbini
    Arthritis Research & Therapy, 19
12345